MA52011A - Vaccins peptidiques contre l'interleukine-31 - Google Patents

Vaccins peptidiques contre l'interleukine-31

Info

Publication number
MA52011A
MA52011A MA052011A MA52011A MA52011A MA 52011 A MA52011 A MA 52011A MA 052011 A MA052011 A MA 052011A MA 52011 A MA52011 A MA 52011A MA 52011 A MA52011 A MA 52011A
Authority
MA
Morocco
Prior art keywords
vaccines against
against interleukin
peptidic
peptidic vaccines
interleukin
Prior art date
Application number
MA052011A
Other languages
English (en)
Inventor
Gary Francis Bammert
Steven Alan Dunham
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of MA52011A publication Critical patent/MA52011A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/00114—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
MA052011A 2018-03-16 2019-03-18 Vaccins peptidiques contre l'interleukine-31 MA52011A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862643921P 2018-03-16 2018-03-16

Publications (1)

Publication Number Publication Date
MA52011A true MA52011A (fr) 2021-01-20

Family

ID=66102208

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052011A MA52011A (fr) 2018-03-16 2019-03-18 Vaccins peptidiques contre l'interleukine-31

Country Status (11)

Country Link
US (3) US11433139B2 (fr)
EP (1) EP3765069A1 (fr)
JP (1) JP7497293B2 (fr)
KR (1) KR102672548B1 (fr)
CN (1) CN112135628B (fr)
AU (1) AU2019236328B2 (fr)
BR (1) BR112020017715A2 (fr)
CA (1) CA3093709C (fr)
MA (1) MA52011A (fr)
MX (2) MX2020009639A (fr)
WO (1) WO2019178601A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3765069A1 (fr) * 2018-03-16 2021-01-20 Zoetis Services LLC Vaccins peptidiques contre l'interleukine-31
WO2021083766A1 (fr) * 2019-10-29 2021-05-06 Evax Ag Traitement du prurit chez les chevaux
EP4247848A4 (fr) * 2020-11-23 2025-10-01 Scout Bio Inc Molécules de liaison à l'antigène et leurs utilisations
CN117222664A (zh) * 2021-01-29 2023-12-12 拜耳动物保健有限责任公司 用于破坏自身耐受的疫苗组合物
BR112023016043A2 (pt) * 2021-02-22 2023-12-05 Zoetis Services Llc Modelo de prurido induzido por il-31 de cavalo
AU2023223603A1 (en) 2022-02-28 2024-08-22 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN.
AR133291A1 (es) * 2023-07-19 2025-09-17 Inst Pasteur De Montevideo Inmunización activa para el tratamiento de la dermatitis atópica
CN119462921B (zh) * 2024-11-12 2025-07-25 苏州恒贞生物科技有限公司 抗TNF-α抗体及其产品和应用

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0190205B1 (fr) 1984-07-24 1992-10-21 Coselco Mimotopes Pty. Ltd. Procede de determination de mimotopes
US5350576A (en) 1991-09-13 1994-09-27 Mycogen Corporation Bacillus thuringiensis isolates for controlling acarides
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
US6194167B1 (en) 1997-02-18 2001-02-27 Washington State University Research Foundation ω-3 fatty acid desaturase
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
GB9823835D0 (en) 1998-10-30 1998-12-23 Univ London Component for vaccine
WO2000056885A1 (fr) 1999-03-18 2000-09-28 Merck Patent Gmbh Proteine permettant de bloquer l'adhesion des plaquettes
EP1130098A3 (fr) 2000-02-29 2003-09-10 Pfizer Products Inc. Osteorégulines mammifères
AU2001236073B2 (en) 2000-03-03 2006-10-19 Kyowa Kirin Co., Ltd. Gene recombinant antibody and its fragment
KR100419555B1 (ko) 2000-05-29 2004-02-19 주식회사유한양행 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자
US6818444B2 (en) 2000-08-04 2004-11-16 Heska Corporation Canine and feline proteins, nucleic acid molecules and uses thereof
GB0024200D0 (en) 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
EP1485126A4 (fr) 2001-12-21 2007-03-21 Idexx Lab Inc Domaines variable d'immunoglobuline canine, anticorps caninises, et procede de production et d'utilisation associes
US20040176283A1 (en) * 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
US20040208870A1 (en) 2003-01-30 2004-10-21 Medimmune, Inc. Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
US20040176823A1 (en) 2003-02-25 2004-09-09 Island Tobin C. Acne treatment device and method
DE602004031341D1 (de) 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
ES2356154T3 (es) 2003-07-21 2011-04-05 Transgene S.A. Citoquinas multifuncionales.
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
JP2008528039A (ja) * 2005-01-28 2008-07-31 ザイモジェネティクス，インコーポレイティド Ｉｌ−３１の均質調製物
CA2595939C (fr) 2005-02-14 2014-08-19 Zymogenetics Inc. Procedes de prediction de reponse therapeutiques dans la dermatite atopique aux antagonistes il-31
EP1858924A1 (fr) 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methodes de traitement d'affections de la peau en employant un antagoniste de il-31ra
JP2008535823A (ja) 2005-03-25 2008-09-04 キュラジェン コーポレイション テネイシンの主要な抗原に対する抗体
US20130216542A1 (en) * 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
EP2301969B1 (fr) 2005-05-06 2015-12-23 ZymoGenetics, Inc. Anticorps monoclonaux IL-31 et procédés d'utilisation
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
AU2007254715B2 (en) 2005-05-06 2013-08-29 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using IL-31 antagonists
EP1777523A1 (fr) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthode pour pronostiquer la progression d'un cancer et les résultats du patient et les moyens pour performer la méthode
JP5230022B2 (ja) 2006-08-09 2013-07-10 ベイラー リサーチ インスティテュート 抗インターフェロンアルファモノクローナル抗体及び使用方法
PT2594586E (pt) 2006-09-01 2014-11-26 Zymogenetics Inc Anticorpos monoclonais de il-31 e métodos de utilização
ES2660036T3 (es) 2007-12-07 2018-03-20 Zymogenetics, Inc. Moléculas de anticuerpo humanizadas específicas para IL-31
EP2254592B1 (fr) 2008-02-28 2019-06-05 Dako Denmark A/S Multimères de mhc dans le diagnostic et le traitement de la borréliose
JP5450985B2 (ja) 2008-06-06 2014-03-26 三郎 齋藤 真核細胞において組換えタンパク質を細胞外に放出させるためのポリヌクレオチド
NZ621834A (en) 2008-06-27 2015-10-30 Zoetis Services Llc Novel adjuvant compositions
BRPI0917459B1 (pt) 2008-08-20 2017-09-12 Zoetis Services Llc N-methyl-1- [trans-4- [methyl (7h-pyrrol [2,3-d] pyridol [2,3-d] pyrimidine compounds, use of these in therapy and crystalline a form of n-methyl- pyrimidin-4-yl) amino] cyclohexyl} methanosulphonamide
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
WO2010037402A1 (fr) 2008-10-02 2010-04-08 Dako Denmark A/S Vaccins moléculaires contre les maladies infectieuses
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2011065935A1 (fr) 2009-11-24 2011-06-03 Cornell University Procédés de production d'anticorps monoclonaux
CA2757287C (fr) 2009-03-31 2019-09-10 East Carolina University Cytokines et neuroantigenes utilises dans le traitement de maladies immunitaires
WO2010117448A2 (fr) 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Immunocytokines chimériques et leurs procédés d'utilisation
BR112012008833A2 (pt) 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
KR20230044026A (ko) 2010-02-24 2023-03-31 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
US10087408B2 (en) 2010-07-07 2018-10-02 The University Of British Columbia System and method for microfluidic cell culture
WO2012008037A1 (fr) 2010-07-15 2012-01-19 富士通株式会社 Appareil de décodage d'image animée, procédé de décodage d'image animée, appareil de codage d'image animée et procédé de codage d'image animée
US9188593B2 (en) 2010-07-16 2015-11-17 The University Of British Columbia Methods for assaying cellular binding interactions
MX344972B (es) * 2010-11-16 2017-01-12 Selecta Biosciences Inc Oligonucleotidos inmunoestimulantes.
WO2012116715A1 (fr) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination chez des nouveaux-nés et des enfants en bas âge
WO2012116714A1 (fr) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination chez des patients âgés
US20140342178A1 (en) 2011-06-28 2014-11-20 Furukawa Electric Co., Ltd. Electrolytic copper foil, and circuit board and flexible circuit board using the electrolytic copper foil
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CA2906231C (fr) 2013-03-28 2024-05-14 Marketa RICICOVA Dispositifs microfluidiques et procedes d'utilisation correspondants dans des dosages multicellulaires de secretion
EP3003350B1 (fr) 2013-05-27 2018-02-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Modulation ciblée de macrophages
AU2014310935B2 (en) 2013-08-21 2019-11-21 CureVac SE Combination vaccine
EP3142692B1 (fr) 2014-05-12 2019-05-01 Technion Research & Development Foundation Limited Compositions contenant l'il-31 et leurs utilisations
EP3872191B1 (fr) 2014-05-22 2024-11-06 The University of British Columbia Procédés permettant de déterminer des paires de chaînes des récepteurs de lymphocytes
MA40824A (fr) 2014-10-22 2017-08-29 Saiba Gmbh Particules de cmv de type virus modifié
EP3209382B1 (fr) 2014-10-24 2020-11-25 Calidi Biotherapeutics, Inc. Technique d'immunotherapie combinee pour le traitement du cancer
CA2974632A1 (fr) 2015-02-04 2016-08-11 The University Of British Columbia Procedes et dispositifs pour l'analyse de particules
BR112018003967A2 (en) 2015-09-08 2018-09-25 Universität Zürich Insect bite hypersensitivity treatment
CA2998390A1 (fr) 2015-09-28 2017-04-06 East Carolina University Adjuvants a base d'aluminium pour une vaccination tolerogene
US20180000912A1 (en) 2016-03-04 2018-01-04 New York University Virus Vectors Expressing Multiple Epitopes of Tumor Associated Antigens For Inducing Antitumor Immunity
AR108333A1 (es) 2016-04-27 2018-08-08 Benchmark Animal Health Ltd Tratamiento de la dermatitis atópica canina
WO2018112363A1 (fr) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Méthodes de traitement du cancer à l'aide de parabacteroides
WO2018156180A1 (fr) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anticorps anti-il31 à usage vétérinaire
WO2018156367A1 (fr) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anticorps anti-il31 à usage vétérinaire
CA3054389A1 (fr) * 2017-03-07 2018-09-13 Universitat Zurich Traitement du prurit chez les chevaux
JP7369690B2 (ja) 2017-09-08 2023-10-26 エヴェロ バイオサイエンシズ，インコーポレーテッド 細菌の細胞外小胞
CA3075270A1 (fr) 2017-09-08 2019-03-14 Evelo Biosciences, Inc. Vesicules extracellulaires provenant de prevotella
WO2019075452A1 (fr) 2017-10-13 2019-04-18 Evelo Biosciences, Inc. Identification de bactéries pour la cancérothérapie
WO2019086694A1 (fr) 2017-11-06 2019-05-09 Geert Mudde Vaccin et antigène il31
CA3085318A1 (fr) 2017-12-11 2019-06-20 Ubi Ip Holdings Immunogenes peptidiques d'il-31 et formulations correspondantes pour le traitement et/ou la prevention de la dermatite atopique
EP3765069A1 (fr) * 2018-03-16 2021-01-20 Zoetis Services LLC Vaccins peptidiques contre l'interleukine-31
CA3093539A1 (fr) 2018-03-16 2019-09-19 Zoetis Services Llc Anticorps monoclonaux anti-interleukine-31 a usage veterinaire
EP3801604A1 (fr) 2018-05-28 2021-04-14 Evax AG Traitement de l'urticaire
JP7535494B2 (ja) 2018-07-19 2024-08-16 オンコホスト リミテッド 癌に対するマクロファージベースの養子細胞療法の有効性を改善するｉｌ－３１
MX2021007446A (es) 2018-12-19 2021-09-08 United Biomedical Inc Epítopos artificiales promiscuos de linfocitos t colaboradores como estimuladores inmunes para inmunógenos peptídicos sintéticos.
IL319030A (en) 2018-12-20 2025-04-01 Saiba AG CMV virus-like particles modified by fusion

Also Published As

Publication number Publication date
CN112135628A (zh) 2020-12-25
MX2025011262A (es) 2025-10-01
MX2020009639A (es) 2021-01-08
EP3765069A1 (fr) 2021-01-20
JP7497293B2 (ja) 2024-06-10
CN112135628B (zh) 2024-11-22
WO2019178601A1 (fr) 2019-09-19
JP2021515800A (ja) 2021-06-24
AU2019236328A1 (en) 2020-09-10
CA3093709A1 (fr) 2019-09-19
BR112020017715A2 (pt) 2020-12-29
RU2020129452A (ru) 2022-04-18
US12343402B2 (en) 2025-07-01
RU2020129452A3 (fr) 2022-04-18
KR20200142010A (ko) 2020-12-21
AU2019236328B2 (en) 2025-10-09
US20220362391A1 (en) 2022-11-17
US20190282704A1 (en) 2019-09-19
KR102672548B1 (ko) 2024-06-04
US20250325685A1 (en) 2025-10-23
WO2019178601A9 (fr) 2020-02-20
US11433139B2 (en) 2022-09-06
CA3093709C (fr) 2024-03-26

Similar Documents

Publication Publication Date Title
MA47677A (fr) Vaccins peptidiques
MA50813A (fr) Vaccins contre le virus d'epstein-barr
MA52011A (fr) Vaccins peptidiques contre l'interleukine-31
EP4153730A4 (fr) Vaccins contre le sars-cov-2
MA49463A (fr) Vaccin contre le virus de l'herpès simplex
EP3668522A4 (fr) Vaccins à base d'arnm efficaces
EP3364981A4 (fr) Vaccin contre le cytomégalovirus humain
EP3700565A4 (fr) Vaccins avec adjuvant
MA46584A (fr) Vaccin contre le cytomégalovirus humain
EP3585803A4 (fr) Formulations de vaccin pneumococcique conjugué
MA46024A (fr) Vaccin contre le virus de l'herpès simplex
IL275208A (en) Hsp90-targeting conjugates and formulations thereof
MA53543A (fr) Vaccins peptidiques
IL277791A (en) HSP90 targeting conjugates and their formulations
MA52180A (fr) Vaccins thérapeutiques anti-abêta
IL284233A (en) Norovirus vaccine: formulations and methods
PL3784026T3 (pl) Dmuchawa
EP3515929A4 (fr) Vaccins thérapeutiques contre le virus de l'hépatite b
EP3429581A4 (fr) Formulations d'énalapril
GB201910794D0 (en) Vaccine
EP3710041A4 (fr) Formulations peptidiques à libération prolongée
ES3049399T3 (en) Combination vaccine
EP3897691A4 (fr) Vaccins contenant de l'il-10 et leurs utilisations
EP3781195A4 (fr) Antigènes vaccinaux chimériques contre l'anaplasmose
EP4323377A4 (fr) Vaccins